P. Niemeyer (Munich, DE)

OCM Orthopädische Chirurgie München
Professor Philipp Niemeyer Philipp Niemeyer is Consultant Surgeon at the OCM in Munich; Germany (Orthopädische Chirurgie München). After graduating from the University of Freiburg in 2002; he began his clinical training at the Department of Orthopaedics at the University of Heidelberg (Germany; Prof. Dr. V. Ewerbeck); which he continued in the Department of Orthopedics and Traumatology at the University of Freiburg. Since that time; he conducts research into preclinical and clinical aspects of the regeneration of cartilage tissue. In addition to publishing various scientific papers in this area he was awarded in 2005 with the Kurt Steim Award of the University of Freiburg in 2012 and the Research Prize of the German Society for Orthopaedics and Orthopaedic Surgery (DGOOC). In 2013 he became Associate Professor at the Freiburg University; he is executive board member of the German-Speaking Society for Arthroscopy and Joint Surgery (AGA) and the German Knee Society (DKG). Furthermore; he is initiator of the German Cartilage Registry which has been introduced in 2013. Since 2016; Philipp Niemeyer is Consultant Surgeon at the OCM in Munich; Germany (Orthopädische Chirurgie München).

Presenter Of 4 Presentations

Extended Abstract (for invited Faculty only) Please select your topic

1.1.2 - Cartilage Repair - The Register Perspective

Presentation Topic
Please select your topic
Date
12.04.2022
Lecture Time
12:15 - 12:30
Room
Potsdam 1
Session Type
Special Session
Extended Abstract (for invited Faculty only) Please select your topic

6.3.1 - The Importance of Cartilage Regeneration: Why, When and How (my Experience With Hyalofast & Nanofx)

Presentation Topic
Please select your topic
Date
13.04.2022
Lecture Time
07:30 - 07:41
Room
Bellevue
Session Type
Industry Satellite Symposium
Extended Abstract (for invited Faculty only) Please select your topic

9.3.3 - Spherox PhIII Study/ Patella Subgroup Analysis & Paediatric Population

Presentation Topic
Please select your topic
Date
13.04.2022
Lecture Time
12:20 - 12:30
Room
Bellevue
Session Type
Industry Satellite Symposium
Podium Presentation Cartilage /Cell Transplantation

18.1.7 - Propensity Score Matched Pair Analysis: Matrix-Associated Autologous Chondrocyte Implantation (M-ACI) Versus Microfracture (MFx)

Abstract

Purpose

In a propensity score matched pair analysis using data from two phase III studies, M-ACI with an in-situ cross-linking hydrogel as chondrocyte carrier (NOVOCART® Inject plus) was compared to MFx in patients with focal knee cartilage defects.

Methods and Materials

The propensity score was estimated using the preoperative KOOS, duration of symptoms, previous knee surgeries, age and sex using a logistic regression model, resulting in 144 patients in the matched pair set (72 per group). The primary endpoint was the change in total KOOS from baseline to the 24-month assessment.

Results

Both groups were comparable regarding baseline KOOS, gender, age, body-mass index, duration of symptoms, smoking status and previous knee surgeries. Individual defect sizes in the M-ACI group were significantly larger than in the MFx group (4.8 cm2 vs. 3.4 cm2). Further differences concerned defect location (no patellar or tibial defects in MFx), number of defects (M-ACI group: 33.3 % with two defects vs. MFx: 9.7%) and defect etiology (more patients with degenerative lesions in the M-ACI group). Both the absolute KOOS ​​and the KOOS changes from baseline at 24 months were higher in the M-ACI group (absolute KOOS: M-ACI 81.8 ± 16.8 vs. MFx 73.0 ± 20.6, KOOS change: M-ACI 40.1 ± 19.5 vs. MFx 30.6 ± 26.1). Treatment contrasts indicated statistically significant superiority of M-ACI from Month 3 up to Month 24 (p = 0.0026). Significant and clinically meaningful differences in favor of M-ACI at 24 months were also found for IKDC changes from baseline (37.8 points vs. 30.4 points, p = 0.0334), KOOS (94.4% vs. 65.3%, p <0.0001) and IKDC responder rates (83.3% vs. 61.1%, p = 0.0126).

Conclusion

In this explorative analysis, M-ACI with NOVOCART® Inject plus has demonstrated superior clinical outcomes compared to MFx in patients with knee cartilage defects during the 2-years follow-up.

Collapse

Moderator Of 1 Session

Potsdam 1 Special Session
Session Type
Special Session
Date
12.04.2022
Time
14:30 - 15:30
Room
Potsdam 1
Session Description
Arthroscopy has become the hallmark of joint pathology treatment also in the cartilage defect. The scientific society of AGA is hosting this session.
Session Learning Objective
  1. Participants should understand the possibilities and problems of arthroscopic approaches in cartilage repair. New innovative arthroscopic treatment options in various joints will be presented and clinical results discussed.
CME Evaluation